TP53 and acute myeloid leukemia: This type of TP53 mutation is heterogeneous, but the most common types of TP53 mutation in AML are mainly missense mutations in the DNA-binding domain, which are not only characterized by loss of function in view of loss of effective DNA sensing of the target sequence and resultant physiologic regulatory function and/or dominant-negative effect, but are also often characterized by gain of function in terms of gain of mutated oncogenic p53 proteins contributing to the malignant phenotype.